Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
|Slideshows|January 7, 2019
Fibromyalgia Pain & Cognitive Impairment: New Insights
Author(s)Mark L. Fuerst
Recent studies address two of the most troubling symptoms of fibromyalgia: pain and cognitive impairment.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement